87582 Federal Register / Vol. 89, No. 213 / Monday, November 4, 2024 / Notices 

information to the U.S. NAC. These 

forms will not only address the 

biosafety and biosecurity containment 

emergency elements of the GAP 

standard but will also inform the U.S. 

NAC risk assessments and thereby, 

guide CDC’s determination of the 

emergency response level and direction. 

The information collected in the 

Personal Protective Equipment (PPE) 

Survey for Laboratories will assist the 

CDC, U.S. NAC and NIOSH with 

developing guidance and 

recommendations for PPE selection and 

use in support of poliovirus 

containment as well as identify 

laboratory PPE commonly used to 

evaluate laboratory PPE performance 

characteristics in testing studies. 

Information collected in the GAP 

Poliovirus Containment PoliovirusEssential Facility Assessment Checklist 

will aid U.S. facilities in preparing for 

an audit to obtain a poliovirus 

certificate of containment. Data 

collected from the GAP Poliovirus 

Containment Poliovirus-Essential 

Facility Questionnaire will collect 

additional information on poliovirus 

materials held by a U.S. facility, their 

work activities, and facility features. 

The Poliovirus Containment Sampling 

Plan and Sanitation Assessment Form 

for Wastewater (WW) Systems 

Supporting a Poliovirus-Essential 

Facility (PEF) in the United States will 

collect information to assess poliovirus 

essential facility’s wastewater system, 

the primary safeguards to reduce and 

control the release of poliovirus from 

the facility. In addition, it will verify the 

safeguards of local wastewater utilities 

that receive wastewater from the PEF. 

The Appeals and Complaints form is 

a new form that will be made available 

by the U.S. NAC of Poliovirus and will 

allow facilities or persons to appeal or 

forward complaints based on services 

provided. This form can be used to 

appeal or initiate complaints with 

regards to specific survey outreach that 

had been conducted or decisions 

rendered by the audit team after an 

audit. 

OMB approval is sought for three 

years. The annualized estimated time 

burden for this information collection is 

129 hours. There is no cost to 

respondents other than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden 

(in hours) 

Facility Staff/Leadership .... Facility Incident Reporting Form for Poliovirus Release or Potential Exposure.10 1 45/60 8 

Facility Staff/Leadership .... Facility Incident Reporting Form for Poliovirus Theft 

or Loss.

10 1 45/60 8 

Facility Staff/Leadership .... Personal Protective Equipment Survey for Laboratories.20 1 1.5 30 

Facility Staff/Leadership .... GAP Poliovirus Containment Poliovirus-Essential Facility Questionnaire.20 1 1.5 30 

Facility Staff/Leadership .... GAP Facility Assessment Checklist ............................ 20 1 1 20 

Facility Staff/Leadership .... The Poliovirus Containment Sampling Plan and Sanitation Assessment Form for Wastewater (WW) 

Systems Supporting a Poliovirus-Essential Facility 

(PEF) in the United States.

20 1 1.5 30 

Facility Staff/Leadership .... U.S. National Authority of Containment of Poliovirus 

‘‘Appeals and Complaints Form’’.

10 1 15/60 3 

Total ............................ ...................................................................................... .................... ........................ .................... 129 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–25557 Filed 11–1–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day-25–0666] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled ‘‘National 

Healthcare Safety Network’’ to the 

Office of Management and Budget 

(OMB) for review and approval. CDC 

previously published a ‘‘Proposed Data 

Collection Submitted for Public 

Comment and Recommendations’’ 

notice on April 23, 2024 to obtain 

comments from the public and affected 

agencies. CDC received two comments 

related to the previous notice. This 

notice serves to allow an additional 30 

days for public and affected agency 

comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 213 / Monday, November 4, 2024 / Notices 87583 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

National Healthcare Safety Network 

(NHSN) (OMB Control No. 0920–0666, 

Exp. 06/30/2026)—Revision—National 

Center for Emerging and Zoonotic 

Infectious Diseases (NCEZID), Centers 

for Disease Control and Prevention 

(CDC). 

Background and Brief Description 

The Division of Healthcare Quality 

Promotion (DHQP), National Center for 

Emerging and Zoonotic Infectious 

Diseases (NCEZID), Centers for Disease 

Control and Prevention (CDC) collects 

data from healthcare facilities in the 

National Healthcare Safety Network 

(NHSN) under OMB Control Number 

0920–0666. NHSN provides facilities, 

health departments, states, regions, and 

the nation with data necessary to 

identify problem areas, measure the 

progress of prevention efforts, and 

ultimately eliminate healthcareassociated infections (HAIs) nationwide. 

NHSN also allows healthcare facilities 

to track blood safety errors and various 

HAI prevention practice methods such 

as healthcare personnel influenza 

vaccine status and corresponding 

infection control adherence rates. 

The proposed changes in this new ICR 

includes revisions made to 74 approved 

NHSN data collection tools and 10 new 

forms, for a total of 84 forms in this 

package. CDC requests OMB approval 

for an estimated 4,398,109 annual 

burden hours. There is no cost to 

respondents other than their time to 

participate. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form number & name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(min./hour 60) 

1 .......... 57.100 NHSN Registration Form ............................................................................... 2,000 1 5/60 

2 .......... 57.101 Facility Contact Information ........................................................................... 2,000 1 10/60 

3 .......... 57.102 NHSN Help Desk Customer Satisfaction Survey .......................................... 26,400 1 2/60 

4 .......... 57.103 Patient Safety Component—Annual Hospital Survey .................................... 5,400 1 137/60 

5 .......... 57.104 NHSN Facility Administrator Change Request Form .................................... 800 1 5/60 

6 .......... 57.105 Group Contact Information ............................................................................. 1,000 1 5/60 

7 .......... 57.106 Patient Safety Monthly Reporting Plan .......................................................... 7,821 12 15/60

8 .......... 57.108 Primary Bloodstream Infection (BSI) ............................................................. 6,000 12 42/60 

9 .......... 57.111 Pneumonia (PNEU) ........................................................................................ 1,800 2 34/60 

10 ........ 57.112 Ventilator-Associated Event (VAE) ................................................................ 5,463 8 32/60

11 ........ 57.113 Pediatric Ventilator-Associated Event (PedVAE) ........................................... 334 1 34/60 

12 ........ 57.114 Urinary Tract Infection (UTI) .......................................................................... 6,000 12 24/60 

13 ........ 57.115 Custom Event ................................................................................................. 600 91 39/60 

14 ........ 57.116 Denominators for Neonatal Intensive Care Unit (NICU) ............................... 1,100 12 240/60 

15 ........ 57.117 Denominators for Specialty Care Area (SCA)/Oncology (ONC) ................... 500 12 300/60 

16 ........ 57.118 Denominators for Intensive Care Unit (ICU)/Other locations (not NICU or 

SCA).

5,500 60 300/60 

17 ........ 57.120 Surgical Site Infection (SSI) ........................................................................... 3,800 12 14/60 

18 ........ 57.121 Denominator for Procedure ............................................................................ 3,800 12 14/60 

19 ........ 57.122 HAI Progress Report State Health Department Survey ................................ 55 1 50/60 

20 ........ 57.123 Antimicrobial Use and Resistance (AUR)—Microbiology Data Electronic 

Upload Specification Tables—Initial Set-up.

2,200 1 4,800/60 

57.123 Antimicrobial Use and Resistance (AUR)—Microbiology Data Electronic 

Upload Specification Tables—Yearly Maintenance.

3,300 2 120/60 

57.123 Antimicrobial Use and Resistance (AUR)—Microbiology Data Electronic 

Upload Specification Tables—Monthly.

5,500 12 5/60 

21 ........ 57.124 Antimicrobial Use and Resistance (AUR)—Pharmacy Data Electronic 

Upload Specification Tables—Initial Set-up.

1,500 1 2,400/60 

57.124 Antimicrobial Use and Resistance (AUR)—Pharmacy Data Electronic 

Upload Specification Tables—Yearly Maintenance.

4,000 1 120/60 

57.124 Antimicrobial Use and Resistance (AUR)—Pharmacy Data Electronic 

Upload Specification Tables—Monthly.

5,500 12 5/60 

22 ........ 57.125 Central Line Insertion Practices Adherence Monitoring ................................ 500 213 26/60 

23 ........ 57.126 MDRO or CDI Infection Form ........................................................................ 720 12 34/60

24 ........ 57.127 MDRO and CDI Prevention Process and Outcome Measures Monthly 

Monitoring.

5,500 29 15/60 

25 ........ 57.128 Laboratory-identified MDRO or CDI Event .................................................... 4,800 12 24/60 

26 ........ 57.129 Adult Sepsis ................................................................................................... 50 12 28/60 

27 ........ 57.130 Pathogens of High Consequence .................................................................. 3,650 365 30/60

28 ........ 57.132 Patient Safety Component Digital Measure Reporting Plan (HOB, HT–CDI, 

VTE, Adult Sepsis, RPS, NVAP)-IT Initial Set up.

5,500 1 1,620/60 

57.132 Patient Safety Component Digital Measure Reporting Plan (HOB, HT–CDI, 

VTE, Adult Sepsis, RPS, NVAP)-IT Yearly Maintenance.

5,500 1 1,200/60 

57.132 Patient Safety Component Digital Measure Reporting Plan (HOB, HT–CDI, 

VTE, Adult Sepsis, RPS, NVAP)-Infection Preventionist.

5,500 4 10/60 

57.132 Patient Safety Digital Reporting Plan (RPS CSV) ......................................... 5,500 365 2/60 


lotter on DSK11XQN23PROD with NOTICES1
87584 Federal Register / Vol. 89, No. 213 / Monday, November 4, 2024 / Notices 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Form number & name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(min./hour 60) 

29 ........ 57.133 Patient Safety Attestation ............................................................................... 3,500 1 10/60 

30 ........ 57.137 Long-Term Care Facility Component—Annual Facility Survey ..................... 6,270 1 135/60 

31 ........ 57.138 Laboratory-identified MDRO or CDI Event for LTCF ..................................... 286 24 23/60 

32 ........ 57.139 MDRO and CDI Prevention Process Measures Monthly Monitoring for 

LTCF.

738 12 10/60 

33 ........ 57.140 Urinary Tract Infection (UTI) for LTCF ........................................................... 373 24 38/60 

34 ........ 57.141 Monthly Reporting Plan for LTCF .................................................................. 546 12 5/60 

35 ........ 57.142 Denominators for LTCF Locations ................................................................. 724 12 35/60 

36 ........ 57.143 Prevention Process Measures Monthly Monitoring for LTCF ........................ 434 12 5/60 

37 ........ 57.145 Long Term Care Antimicrobial Use (LTC–AU) Module CDA ........................ 16,500 12 5/60 

38 ........ 57.150 LTAC Annual Survey ..................................................................................... 395 1 102/60 

39 ........ 57.151 Rehab Annual Survey .................................................................................... 395 1 102/60 

40 ........ 57.211 Weekly Healthcare Personnel Influenza Vaccination Cumulative Summary 

for Non-Long-Term Care Facilities-Manual.

117 12 25/60 

57.211 Weekly Healthcare Personnel Influenza Vaccination Cumulative Summary 

for Non-Long-Term Care Facilities-.CSV.

3,080 12 20/60 

41 ........ 57.214 Annual Healthcare Personnel Influenza Vaccination Summary-Manual ....... 22,000 1 120/60 

57.214 Annual Healthcare Personnel Influenza Vaccination Summary-.CSV .......... 1,920 1 55/60 

42 ........ 57.215 Seasonal Survey on Influenza Vaccination Programs for Healthcare Personnel.15,426 1 45/60 

43 ........ 57.300 Hemovigilance Module Annual Survey .......................................................... 63 1 86/60 

44 ........ 57.301 Hemovigilance Module Monthly Reporting Plan ............................................ 108 12 1/60 

45 ........ 57.302 Hemovigilance Module Monthly Incident Summary ....................................... 9 12 30/60 

46 ........ 57.303 Hemovigilance Module Monthly Reporting Denominators ............................. 102 12 70/60 

47 ........ 57.305 Hemovigilance Incident .................................................................................. 13 77 10/60 

48 ........ 57.306 Hemovigilance Module Annual Survey—Non-acute care facility .................. 20 1 35/60 

49 ........ 57.307 Hemovigilance Adverse Reaction—Acute Hemolytic Transfusion Reaction 8 2 22/60 

50 ........ 57.308 Hemovigilance Adverse Reaction—Allergic Transfusion Reaction ............... 50 11 22/60 

51 ........ 57.309 Hemovigilance Adverse Reaction—Delayed Hemolytic Transfusion Reaction.9 2 20/60 

52 ........ 57.310 Hemovigilance Adverse Reaction—Delayed Serologic Transfusion Reaction.19 5 20/60 

53 ........ 57.311 Hemovigilance Adverse Reaction—Febrile Non-hemolytic Transfusion Reaction.85 13 20/60 

54 ........ 57.312 Hemovigilance Adverse Reaction—Hypotensive Transfusion Reaction ....... 23 3 20/60 

55 ........ 57.313 Hemovigilance Adverse Reaction—Infection ................................................. 2 2 20/60 

56 ........ 57.314 Hemovigilance Adverse Reaction—Post Transfusion Purpura ..................... 1 1 20/60 

57 ........ 57.315 Hemovigilance Adverse Reaction—Transfusion Associated Dyspnea ......... 18 3 20/60 

58 ........ 57.316 Hemovigilance Adverse Reaction—Transfusion Associated Graft vs. Host 

Disease.

1 1 20/60 

59 ........ 57.317 Hemovigilance Adverse Reaction—Transfusion Related Acute Lung Injury 1 1 20/60 

60 ........ 57.318 Hemovigilance Adverse Reaction—Transfusion Associated Circulatory 

Overload.

40 4 21/60 

61 ........ 57.319 Hemovigilance Adverse Reaction—Unknown Transfusion Reaction ............ 15 3 20/60 

62 ........ 57.320 Hemovigilance Adverse Reaction—Other Transfusion Reaction .................. 39 3 20/60 

63 ........ 57.400 Outpatient Procedure Component—Annual Ambulatory Surgery Center 

Survey.

350 1 10/60 

64 ........ 57.401 Outpatient Procedure Component—Monthly Reporting Plan ........................ 350 12 10/60 

65 ........ 57.402 Outpatient Procedure Component Same Day Outcome Measures .............. 50 1 43/60 

66 ........ 57.403 Outpatient Procedure Component—Denominators for Same Day Outcome 

Measures.

50 400 20/60 

67 ........ 57.404 Outpatient Procedure Component—SSI Denominator .................................. 300 100 23/60 

68 ........ 57.405 Outpatient Procedure Component—Surgical Site (SSI) Event ..................... 300 36 40/60 

69 ........ 57.408 Monthly Survey Patient Days & Nurse Staffing ............................................. 2,500 12 300/60 

70 ........ 57.500 Outpatient Dialysis Center Practices Survey ................................................. 6,900 1 150/60 

71 ........ 57.501 Dialysis Monthly Reporting Plan .................................................................... 7,400 12 5/60 

72 ........ 57.502 Dialysis Event ................................................................................................. 7,400 30 50/60 

73 ........ 57.503 Denominator for Outpatient Dialysis .............................................................. 7,400 12 10/60 

74 ........ 57.504 Prevention Process Measures Monthly Monitoring for Dialysis .................... 1,730 12 60/60 

75 ........ 57.507 Home Dialysis Center Practices Survey ........................................................ 550 1 65/60 

76 ........ 57.600 Neonatal Component FHIR Measure-Late Onset Sepsis Meningitis 

(LOSMEN) Module-IT Initial Set up.

5,500 1 1,620/60 

57.600 Neonatal Component FHIR Measure-Late Onset Sepsis Meningitis 

(LOSMEN) Module-IT Yearly Maintenance.

5,500 1 1,200/60 

57.600 Neonatal Component FHIR Measure-Late Onset Sepsis Meningitis 

(LOSMEN) Module-Infection Preventionist.

5,500 6 6/60 

57.600 Neonatal Component Late Onset Sepsis Meningitis (LOSMEN) Module 

CDA Data Collection-Infection Preventionist.

5,500 12 2/60 

77 ........ 57.601 Late Onset Sepsis/Meningitis Denominator Form: Late Onset Sepsis/Meningitis Denominator Form: Data Table for monthly electronic upload.300 6 5/60 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 213 / Monday, November 4, 2024 / Notices 87585 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Form number & name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(min./hour 60) 

78 ........ 57.602 Late Onset Sepsis/Meningitis Event Form: Data Table for Monthly Electronic Upload.300 6 6/60 

79 ........ 57.700 Medication Safety-Digital Measure Reporting Plan (HYPO, HAKI, ORAE)— 

IT Initial Set up.

5,500 1 1,620/60 

57.700 Medication Safety-Digital Measure Reporting Plan (HYPO, HAKI, ORAE)— 

IT Yearly Maintenance.

5,500 1 1,200/60 

57.700 Medication Safety-Digital Measure Reporting Plan (HYPO, HAKI, ORAE)— 

Infection Preventionist.

5,500 4 10/60 

80 ........ 57.701 Glycemic Control Module-HYPO Annual Survey ........................................... 10 1 180/60 

81 ........ 57.800 Billing Code Data: 837I Upload ..................................................................... 5,500 4 5/60 

82 ........ 57.801 External Validation Summary Report ............................................................. 20 2 15/60 

83 ........ 57.802 Bed Capacity-IT Initial Set Up ....................................................................... 25 1 20/60 

84 ........ 57.803 All Hazards ..................................................................................................... 540 365 5/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–25552 Filed 11–1–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60-Day–25–25AU; Docket No. CDC–2024– 

0088] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a proposed information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled Risk factors, 

clinical course, presence and 

persistence of virus in various bodily 

fluids, and risk of sexual transmission 

among U.S. adults with Oropouche 

virus (OROV) disease. This study will 

assist in the response to this emerging 

virus by; identifying risk factors for 

infection to inform prevention guidance 

and messaging, informing recognition, 

diagnosis, follow-up care, and 

counseling of patients with OROV 

disease, and understanding risks of 

sexual transmission to inform 

prevention recommendations, especially 

for pregnant people and their partners, 

or those considering pregnancy. 

DATES: CDC must receive written 

comments on or before January 3, 2025. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0088 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; 

Telephone: 404–639–7570; Email: omb@

cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Risk factors, clinical course, presence 

and persistence of virus in various 

bodily fluids, and risk of sexual 

transmission among U.S. adults with 

Oropouche virus (OROV) disease— 

New—National Center for Emerging and 

Zoonotic Infectious Diseases (NCEZID), 

Centers for Disease Control and 

Prevention (CDC). 


lotter on DSK11XQN23PROD with NOTICES1